Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.

By P. Ost, D. Reynders, K. Decaestecker, V. Fonteyne, N. Lumen, A. De Bruycker, B. Lambert, L. Delrue, R. Bultijnck, T. Claeys and 8 more. Journal of Clinical Oncology, 2017

1,115 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/e439680dea391a572fe047e1415383fea4c69f5f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. Christine Lovly
2. Z. Du

Citations in the corpus

• Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study. (2020, neutral): “26,27 30 The cost of diagnostic imaging is increasingly recognised as a major component of health expenditure.”
• Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer (2020, background): “Time to first recurrence, median (range), mo 22 (9-42) 22 (9-51)”
• Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. (2019, methodology): “Eligible patients (1) had pathologically confirmed NSCLC, (2) had stage IV disease according to the seventh edition of the American Joint Committee on Cancer staging system, (3) had three or fewer metastases, not including the primary tumor, (4) had an Eastern Cooperative Oncology Group performance ”